Skip to main content
. 2023 Feb 3;12:e44157. doi: 10.2196/44157

Table 2.

Schedule of events of the Brilhar e Transcender study.


Baseline Week 12 Week 24 Week 36 Week 48 or early terminationa HIV seroconversion visit
Eligibility




Measures

Behavioral, partnership, network, and structural measures

Adverse events


Social harm


Implementation science: participants





Implementation science: coordination




Implementation science: peer navigators




Laboratory procedures

HIV rapid test b b b b

CD4+ and CD8+ cell counts c
c
d

HIV RNA viral load c,d d c,d d c,d

HIV recency testing c




HIV genotyping c




Treponemal syphilis rapid test

Nontreponemal syphilis (venereal disease research laboratory) testing e e e e e

Hepatitis B rapid test


f

Hepatitis B serology g





Hepatitis C rapid test


h

Anti–hepatitis C virus i


i

Hepatitis C viral load j


j

Rectal swab (Chlamydia trachomatis and Neisseria gonorrhoeae)




Dried blood spot (pre-exposure prophylaxis adherence assessment) k k k k k k
Hormone dispensation
Medical or psychiatric visit l l l l l

aWithdrawn or discontinued participants before the final visit.

bOnly for participants with a negative HIV test in the previous visit.

cFor all participants living with HIV.

dOnly for HIV-negative participants with recent HIV exposition according to the service guidelines.

eOnly for those with a positive treponemal test result.

fOnly for a negative hepatitis B rapid test result.

gOnly for a positive hepatitis B rapid test result.

hOnly for those with a negative hepatitis C rapid test result.

iOnly for those with a positive hepatitis C rapid test result.

jOnly for those with positive findings on an anti–hepatitis C virus antibody test.

kOnly for participants receiving pre-exposure prophylaxis, except those initiating pre-exposure prophylaxis at the current visit.

lIf clinically indicated.